Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR

Lawrence J Jennings*, David George, Juliann Czech, Min Yu, Loren Joseph

*Corresponding author for this work

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Monitoring BCR-ABL1 fusion transcripts by real-time quantitative RT-PCR has become an important clinical test for the management of patients with chronic myeloid leukemia. However, it has some inherent limitations with regard to its lower limit of detection and limit of quantification. Improvement in the lower limit of detection could aid clinicians in selecting candidates for discontinuation of tyrosine kinase inhibitors without relapse. Improvement in the limit of quantification may also avoid unnecessary testing or changes in therapy. Here, we demonstrate the advantages of droplet digital RT-PCR with regard to simplicity, lower limit of detection, and limit of quantification. We expect the advantages of droplet digital RT-PCR will make it the preferred method for quantification of BCR-ABL1 fusion transcripts.

Original languageEnglish (US)
Pages (from-to)174-179
Number of pages6
JournalJournal of Molecular Diagnostics
Volume16
Issue number2
DOIs
StatePublished - Mar 1 2014

Fingerprint

Limit of Detection
Polymerase Chain Reaction
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Real-Time Polymerase Chain Reaction
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine

Cite this

Jennings, Lawrence J ; George, David ; Czech, Juliann ; Yu, Min ; Joseph, Loren. / Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. In: Journal of Molecular Diagnostics. 2014 ; Vol. 16, No. 2. pp. 174-179.
@article{ccd5f5c15e4149e093038aff259fa9a8,
title = "Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR",
abstract = "Monitoring BCR-ABL1 fusion transcripts by real-time quantitative RT-PCR has become an important clinical test for the management of patients with chronic myeloid leukemia. However, it has some inherent limitations with regard to its lower limit of detection and limit of quantification. Improvement in the lower limit of detection could aid clinicians in selecting candidates for discontinuation of tyrosine kinase inhibitors without relapse. Improvement in the limit of quantification may also avoid unnecessary testing or changes in therapy. Here, we demonstrate the advantages of droplet digital RT-PCR with regard to simplicity, lower limit of detection, and limit of quantification. We expect the advantages of droplet digital RT-PCR will make it the preferred method for quantification of BCR-ABL1 fusion transcripts.",
author = "Jennings, {Lawrence J} and David George and Juliann Czech and Min Yu and Loren Joseph",
year = "2014",
month = "3",
day = "1",
doi = "10.1016/j.jmoldx.2013.10.007",
language = "English (US)",
volume = "16",
pages = "174--179",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "2",

}

Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. / Jennings, Lawrence J; George, David; Czech, Juliann; Yu, Min; Joseph, Loren.

In: Journal of Molecular Diagnostics, Vol. 16, No. 2, 01.03.2014, p. 174-179.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR

AU - Jennings, Lawrence J

AU - George, David

AU - Czech, Juliann

AU - Yu, Min

AU - Joseph, Loren

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Monitoring BCR-ABL1 fusion transcripts by real-time quantitative RT-PCR has become an important clinical test for the management of patients with chronic myeloid leukemia. However, it has some inherent limitations with regard to its lower limit of detection and limit of quantification. Improvement in the lower limit of detection could aid clinicians in selecting candidates for discontinuation of tyrosine kinase inhibitors without relapse. Improvement in the limit of quantification may also avoid unnecessary testing or changes in therapy. Here, we demonstrate the advantages of droplet digital RT-PCR with regard to simplicity, lower limit of detection, and limit of quantification. We expect the advantages of droplet digital RT-PCR will make it the preferred method for quantification of BCR-ABL1 fusion transcripts.

AB - Monitoring BCR-ABL1 fusion transcripts by real-time quantitative RT-PCR has become an important clinical test for the management of patients with chronic myeloid leukemia. However, it has some inherent limitations with regard to its lower limit of detection and limit of quantification. Improvement in the lower limit of detection could aid clinicians in selecting candidates for discontinuation of tyrosine kinase inhibitors without relapse. Improvement in the limit of quantification may also avoid unnecessary testing or changes in therapy. Here, we demonstrate the advantages of droplet digital RT-PCR with regard to simplicity, lower limit of detection, and limit of quantification. We expect the advantages of droplet digital RT-PCR will make it the preferred method for quantification of BCR-ABL1 fusion transcripts.

UR - http://www.scopus.com/inward/record.url?scp=84894106402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894106402&partnerID=8YFLogxK

U2 - 10.1016/j.jmoldx.2013.10.007

DO - 10.1016/j.jmoldx.2013.10.007

M3 - Article

C2 - 24389534

AN - SCOPUS:84894106402

VL - 16

SP - 174

EP - 179

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 2

ER -